Lackie C L, Luzier A B, Donovan J A, Feras H I, Forrest A
Department of Pharmacy Practice, State University of New York at Buffalo School of Pharmacy, USA.
Clin Ther. 1998 Jul-Aug;20(4):699-710. doi: 10.1016/s0149-2918(98)80133-1.
The objective of this study was to assess a weight-based heparin (WBH) nomogram (80-U/kg bolus, 18-U/kg-per-hour initial infusion) and determine its clinical performance and impact on resource utilization. All patients treated with heparin for venous thromboembolism or unstable angina during a 15-week study period were included in this retrospective, chart-review study. Three groups were identified: patients treated with WBH, patients whose regimen deviated from the weight-based nomogram (DEV), and matched historical controls (HCs). In patients receiving heparin for more than 24 hours, those treated with WBH achieved threshold activated partial thromboplastin time (aPTT) levels significantly faster than did HC or DEV patients. However, 42% of WBH-treated patients were found to have initial supratherapeutic responses. Logistic regression analysis identified age > or =67 years, prior warfarin therapy within 7 days of heparin, and high initial infusion rate as predictive of a supratherapeutic aPTT response; smoking was predictive of a subtherapeutic response. Bleeding events were not significantly different between groups. An infusion rate of 15 U/kg per hour was found to closely approximate our population's actual heparin infusion requirement. Resource utilization was significantly different between the WBH and HC groups in terms of nursing interventions at 48 to 72 hours. We concluded that WBH rapidly drives patients' aPTT response above the therapeutic threshold for heparin; however, prudent adjustment of the initial infusion rate is necessary to avoid a supratherapeutic aPTT response. Our data support a nomogram with an initial infusion rate of 15 U/kg per hour.
本研究的目的是评估基于体重的肝素(WBH)剂量图(80 U/kg静脉推注,初始输注速度为18 U/kg每小时),并确定其临床性能以及对资源利用的影响。在一项为期15周的研究期间,所有接受肝素治疗静脉血栓栓塞或不稳定型心绞痛的患者均纳入本回顾性图表审查研究。确定了三组:接受WBH治疗的患者、治疗方案偏离基于体重剂量图的患者(DEV)以及匹配的历史对照(HC)。在接受肝素治疗超过24小时的患者中,接受WBH治疗的患者达到活化部分凝血活酶时间(aPTT)阈值水平的速度明显快于HC或DEV组患者。然而,发现42%接受WBH治疗的患者最初出现超治疗反应。逻辑回归分析确定年龄≥67岁、肝素治疗前7天内曾接受华法林治疗以及初始输注速度高是超治疗aPTT反应的预测因素;吸烟是亚治疗反应的预测因素。各组之间出血事件无显著差异。发现每小时15 U/kg的输注速度与我们研究人群的实际肝素输注需求密切接近。在48至72小时的护理干预方面,WBH组和HC组之间的资源利用存在显著差异。我们得出结论,WBH能迅速使患者的aPTT反应超过肝素的治疗阈值;然而,有必要谨慎调整初始输注速度以避免出现超治疗aPTT反应。我们的数据支持初始输注速度为每小时15 U/kg的剂量图。